4.6 Article

MPZL1 upregulation promotes tumor metastasis and correlates with unfavorable prognosis in non-small cell lung cancer

期刊

CARCINOGENESIS
卷 43, 期 10, 页码 919-929

出版社

OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgac055

关键词

-

类别

资金

  1. National Natural Science Foundation of China (NSFC) project [82072571]
  2. Shanghai Pujiang Scholar Program [19PJ1408500]
  3. Experimental Animal Research Fund, Science and Technology Commission of Shanghai Municipality [19140905600]
  4. Shanghai Young Eastern Scholar Program
  5. Nurture projects for basic research of Shanghai Chest Hospital [2021YNJCM09]
  6. special project of integrated traditional Chinese and Western medicine in general hospital of Shanghai Health Committee [ZHYY-ZXYJHZX-202023]
  7. Shanghai Jiao Tong University School of Medicine Full-time Clinical Research Team Program

向作者/读者索取更多资源

This study found that MPZL1 gene is upregulated in non-small cell lung cancer (NSCLC) and high expression is associated with unfavorable prognosis. Ectopic overexpression of MPZL1 promotes migratory ability of lung cancer cells, while knockdown of MPZL1 impairs migration. By analyzing gene expression, COL11A1 was identified as a potential effector gene positively regulated by MPZL1 and correlated with poor prognosis in NSCLC patients.
Non-small cell lung cancer (NSCLC), accounting for 85% of all lung cancer, is one of the leading causes of cancer-related death worldwide. Previously, we demonstrated that MPZL1 gene amplification promotes liver cancer metastasis through activating Src/Cortactin pathway. However, the clinical relevance and biological roles of the MPZL1 gene in lung cancer are still unknown. Here, we found that MPZL1 expression upregulates in human NSCLC, which is partly due to the copy number amplification of this gene. Next, we observed that high MPZL1 expression correlates with unfavorable prognosis of NSCLC patients. We further demonstrated that ectopic MPZL1 overexpression promotes in vitro migratory but not proliferation and colony formation abilities of both H1299 and H460 cells. Consistently, we found that MPZL1 knockdown impairs the migratory abilities of A549 and H1775 cells. Moreover, we found that MPZL1 knockdown inhibits in vivo metastatic but not tumor growth abilities of the A549 cells. Additionally, a total of 297 differentially expressed genes (DEGs) were identified by RNA sequencing in A549 cells upon MPZL1 knockdown. By integrative analysis of DEGs regulated by MPZL1 in A549 cells and human NSCLC tissues, we revealed that COL11A1 is the potential effector gene that positively regulated by MPZL1 and correlates with poor prognosis of NSCLC patients. In conclusion, our work indicates that one of the mechanisms by which MPZL1 promotes NSCLC metastasis is through upregulating the COL11A1, and MPZL1 can be used as a biomarker to predict the prognosis of NSCLC patients. This study demonstrated that MPZL1 primarily drives tumor metastasis of NSCLC, highlighting that MPZL1 can be used as a biomarker to predict the prognosis of NSCLC patients, and represents a potential therapeutic target to inhibit NSCLC metastasis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据